Abstract 384P
Background
Betel nut chewing might contribute to strong invasion and treatment refractoriness. In western countries where HPV+ OPC prevalence is high, induction TPF response rate in locally advanced HNSCC is around 70%; Erbitux and TP (Argiris in JCO2008) response rate is 86%. In the analysis from KGMH in Taiwan, induction response for locally advanced HNSCC was 55% in betel-nuts chewers compared with 75% in non-users(p=0.038; From Su in World Journal of Surgical Oncology 2016). Erbitux-TPF induction response rate was 88% from VGH in Taiwan by Lu in Head & Neck2019. In our previous study from unresectable stage IVA & IVB betal-nuts related HNSCC patients in ASCO2023, flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion) with Biotherapy(EGFR or VEGFR-targeting)or Bio-immunotherapy had encouraging induction response with favorable toxicity to conversion surgery or definite CCRT.
Methods
Hypopharyngreal cancer in Taiwan in Taiwan often had advaced stage(stage IV 70%) and double cancers easily(esp. lung cancer and esophageal cancer). We prepared to compare the outcomes of different treatment strategies in stage IVA/IVB hypophryngeal cancer, from 2012 to 2023.
Results
Table: 384P
Treatment strategies(total 75 patients) | Definite CCRT 9 | Curative surgery then adjuvant CCRT 14(all receiving total laryngectomy & bilateral neck dissection) | Induction therapy then definite CCRT 29 | Induction therapy then curative surgery then adjuvant CCRT 23 |
Induction response(total 52 patients) | N/A | N/A | 69%(20/29) | 87%(20/23) |
2-year DFS(total 64 patients) | 57.1% | 63.6% | 68% | 81% |
5-year OS(total 50 patients) | 20% | 26.7% | 37.5% | 50% |
All with maintenance UFUR
Conclusions
CCRT is still one standard option; if no need for organ preservation, curative surgery followed by adjuvant CCRT still works in resectable and medically operable patients. Maintenance UFUR yielded relatively favorable 2-year DFS and 5-year OS. Induction Bio-CT or Bio-chemoimmunotherapy followed by CCRT may be promoted beyond TAX323/324. Aggressive induction therapy followed by mini-invasive surgery and then adjuvant CCRT with maintenance UFUR might be administered in selected patients with high induction response. Encouraging outcomes have been shown by sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board in National Taiwan University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract